Ophthalmology
Myopia Rate Increasing in Taiwanese Children
The Downside of Pre-Op Testing for Cataract Surgery
What Drives Noncompliance to AMD Treatment?
Ophthalmology Glaucoma
Endothelial Cell Loss After Baerveldt Implant Surgery
Ophthalmology Retina
Scleral Buckling Plus PPV for Retinal Detachment Repair
American Journal of Ophthalmology
Respiratory Droplets Transmitted During Slit-Lamp Exams
Subtyping Idiopathic Uveitis by Gene Expression
JAMA Ophthalmology
Retinal Vascular Occlusion and Hormone Therapy in Women
Glaucoma Macular Damage Patterns and Visual Disability
FDA Conference Report: Ophthalmic Laser-Based Imaging
Other Journals
Teprotumumab for Inactive TED
Do Structural Changes Truly Precede Functional Changes in Glaucoma?
IRIS Registry Snapshot: Uveitis Dx and Tx
Verana Health analyzed statistically de-identified electronic health record (EHR) data from the Academy’s IRIS Registry to assess the number of uveitis diagnoses in the United States, the location of the uveitis, and the location of steroid injections for treatment. The results include newly diagnosed cases.
Results. All told, 662,925 eyes were diagnosed with uveitis from Jan. 1, 2016, to Nov. 6, 2020, and 193,432 eyes received a steroid injection.
Disease location. Anterior uveitis was diagnosed in 523,120 eyes (78.9%), and posterior disease was diagnosed in 163,678 eyes (24.7%). (Percentages add up to more than 100%, as some eyes had both anterior and posterior disease.)
Injection type. Intravitreal injections took place in 123,210 eyes (63.7%), while 86,664 eyes (44.8%) received sub-Tenon injections. (Percentages add up to more than 100%, as some eyes received injections in both locations.)
Trend rates. During the study period, trends in rates of anterior versus posterior uveitis remained stable, as did the injection site and the number of diagnoses.
Note: The Academy has partnered with Verana Health to curate and analyze IRIS Registry data.